In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

A holiday you would never wish for

Session Discussing the most challenging clinical cases

Speaker Michal Pazdernik

Congress : ESC Congress 2016

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care
  • Session type : Clinical Cases
  • FP Number : 1258

M. Pazdernik1 , I. Netuka1 , J. Maly1 , J. Kettner1 , L. Voska1 , J. Pirk1 , V. Melenovsky1 , J. Kautzner1 , 1Institute for Clinical and Experimental Medicine (IKEM), Department of Cardiology - Prague - Czech Republic ,

European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 1411

Introduction: Giant cell myocarditis (GCM) is known as a rare, rapidly progressive, and frequently fatal myocardial disease in young and middle-aged adults. The most common early manifestations are heart failure, ventricular arrhythmias, and atrioventricular block, but GCM may also disguise as an acute myocardial infarction and rarely presents as an unexpected sudden cardiac death. The diagnosis of GCM rests fully on microscopy of the heart muscle and even in experienced centers >4 in 10 cases may escape detection until autopsy or cardiac transplantation

Case report: This case presents a 64-year old female with insignificant medical history who developed syncope while on holiday as a result of newly documented intermittent 3rd degree AV block. No chest pain or shortness of breath was reported before the event. Laboratory findings showed elevated levels of hsTnT (1086 ng/l, range 0–14) and BNP (2164 ng/l, range 10–155). Echocardiography revealed borderline left ventricle ejection fraction (LV EF 50–55%); coronary angiography revealed no pathology. Suspicion of myocarditis was raised and cardiac MRI and pacemaker implantation were considered. Progression of LV systolic dysfunction was documented (EF 45%) on the 4th post-admission day (PAD). One day after, implantation of 2D-PM was performed (persistent AV block). Subsequent progression of LV systolic dysfunction (EF 30%, diffuse hypokinesis) requiring levosimendan administration was reported on the 7th PAD. Endomyocardial biopsy revealed acute myocarditis with giant-cell granulomas. The progression of low cardiac output with incessant ventricle tachycardia required LVAD Levitronix CentriMag implantation on the 8th PAD, even after combined immunosuppressive therapy and inotropic support. On the 17th PAD, conversion to LVAD Heart Mate II was performed. The patient was indicated for radiofrequency ablation (RFA) for incessant ventricular tachycardia on the 60th PAD. Due to severe aortic regurgitation, which developed during the acute illness after LVAD implantation, TAVI was performed (transfemoral implantation with an EvolutR 23 mm valve) on the 138th PAD. 6 months after the initial signs of fulminant myocarditis, the patient underwent heart transplantation (HTx); 2 months later, after surviving a complicated postoperative course, she was repatriated to her country of origin in a healthy condition.

Summary: We report a rare case of GCM in a 64-year old, previously healthy female, complicated by rapid development of progressive acute heart failure requiring the comprehensive care of our heart team. Using a broad spectrum of therapeutic approaches (2D-PM, LVAD Levitronix, LVAD Heart Mate II, RF ablation, TAVI) (Image 1), the patient successfully underwent HTx.

Course of in-hospital stay

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are